as of 11-10-2026 3:54pm EST
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 149.2M | IPO Year: | 2019 |
| Target Price: | $8.67 | AVG Volume (30 days): | 490.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $0.88 - $5.19 | Next Earning Date: | 08-20-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Chief Bus. Development Officer
Avg Cost/Share
$0.74
Shares
107,978
Total Value
$79,903.72
Owned After
266,467
SEC Form 4
EVP, Clinical Development
Avg Cost/Share
$0.79
Shares
3,282
Total Value
$2,592.78
Owned After
304,201
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Cao Sean Wuxiong | NBP | Chief Bus. Development Officer | Sep 9, 2026 | Sell | $0.74 | 107,978 | $79,903.72 | 266,467 | |
| Xu Cong Claire | NBP | EVP, Clinical Development | Aug 31, 2026 | Sell | $0.79 | 3,282 | $2,592.78 | 304,201 |
See how NBP stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "NBP NovaBridge Biosciences American Depositary Shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.